British Journal of Haematology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Idarucizumab reversal of anticoagulation in dabigatran-treated patients presenting with acute traumatic injuries: Interim results from the RE-VERSE AD Study
2016
-
Is an aspirate for morphology and flow cytometry really necessary when a trephine is also being performed in the diagnosis and staging of lymphoma?
2014
-
Outcomes of patients with peripheral T-cell lymphoma: a subset analysis of the NCIC Clinical Trials Group LY.12 Phase III clinical trial
2014
-
XAMOS: a non-interventional study comparing oral rivaroxaban with conventional regimens for thromboprophylaxis after major orthopaedic surgery of the hip and knee
2012
-
Weight loss is still a problem with reduced intensity conditioning transplants and modern supportive care
2010
-
Pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery
2009
-
Population and genetic heterogeneity of beta-thalassaemia in Ontario, Canada
2008
-
The oral, direct factor Xa inhibitor rivaroxaban vs enoxaparin for prevention of venous thromboembolism after total knee replacement: RECORD3
2008
-
Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits
2004
-
The entity of CD34+ t (15; 17) acute promyelocytic leukemia
1998
-
Sulphated low molecular weight heparin is a potent inhibitor of intrinsic tenase and prothrombinase.
1998
-
LOW-MOLECULAR-WEIGHT HEPARIN IN THE TREATMENT AND PROPHYLAXIS OF THROMBOSIS
1992
-
GENE PROBE ANALYSIS OF HODGKINS AND NON-HODGKINS LYMPHOMAS
1988
-
ANALYSIS OF T-CELL ASSOCIATED REARRANGEMENT OF THE T-CELL RECEPTOR GAMMA-CHAIN GENES IN B-CLL
1988
-
Genetic predisposition to vaccine-induced immune thrombotic thrombocytopenia.
2024
-
Genome‐wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
205:1889-1898.
2024
-
Past meets present: Reviving 80‐year‐old Canadian dried serum from World War II and its significance in advancing modern freeze‐dried plasma for prehospital management of haemorrhage.
204:1515-1522.
2024
-
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study.
203:781-791.
2023
-
Refractory immune thrombocytopenia in adults: Towards a new definition.
203:23-27.
2023
-
Quality of end‐of‐life care in multiple myeloma: A 13‐year analysis of a population‐based cohort in Ontario, Canada.
199:688-695.
2022
-
Maternal iron deficiency anaemia in pregnancy: Lessons from a national audit.
199:277-284.
2022
-
Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and meta‐analysis.
199:130-142.
2022
-
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
198:93-102.
2022
-
The Aim2Be mHealth Intervention for Children With Overweight or Obesity and Their Parents: Person-Centered Analyses to Uncover Digital Phenotypes.
24:e35285-e35285.
2022
-
Iron chelation therapy in patients with low‐ to intermediate‐risk myelodysplastic syndrome: A systematic review and meta‐analysis.
197:e9-e11.
2022
-
Pharmacologic induction of PGC‐1α stimulates fetal haemoglobin gene expression.
197:97-109.
2022
-
BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
196:136-145.
2022
-
Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on‐treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)‐2 Trial.
196:424-432.
2022
-
Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI).
194:759-766.
2021
-
Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study.
194:319-324.
2021
-
Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria.
194:439-443.
2021
-
Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
193:779-791.
2021
-
Microcytosis in patients with haemoglobin C trait: is α‐thalassaemia trait to blame?.
191:e129-e131.
2020
-
Fatigue in children and adolescents with immune thrombocytopenia.
191:98-106.
2020
-
Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor.
190:594-598.
2020
-
Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian Inherited Marrow Failure Registry.
189:976-981.
2020
-
Experience with ponatinib in paediatric patients with leukaemia.
189:363-368.
2020
-
Increased cytotoxic potential of CD8+ T cells in immune thrombocytopenia.
188:e72-e76.
2020
-
Decision‐analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury.
186:166-168.
2019
-
Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence‐based practice, an international approach.
185:549-562.
2019
-
Cord gas parameters in infants born to women with sickle cell disease: a retrospective matched cohort study.
184:653-657.
2019
-
Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study.
183:457-465.
2018
-
Incidence of intracranial bleeding in anticoagulated patients with minor head injury: a systematic review and meta‐analysis of prospective studies.
183:119-126.
2018
-
Early‐stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long‐term patient outcomes.
182:212-221.
2018
-
A variant Sp1 (R218Q) transcription factor might enhance HbF expression in β0‐thalassaemia homozygotes.
180:755-757.
2018
-
Association between maternal haemoglobin and stillbirth: a cohort study among a multi‐ethnic population in England.
179:829-837.
2017
-
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an MDS‐CAN analysis.
179:83-97.
2017
-
Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.
178:20-31.
2017
-
The effect of rituximab on anti‐platelet autoantibody levels in patients with immune thrombocytopenia.
178:302-307.
2017
-
Molecular structural analysis of a novel and de‐novo mutation in the SERPINC1 gene associated with type 1 antithrombin deficiency.
177:654-656.
2017
-
How do we approach thrombocytopenia in critically ill patients?.
177:27-38.
2017
-
The unique immunological features of heparin‐induced thrombocytopenia.
177:198-207.
2017
-
Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.
174:686-691.
2016
-
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists.
174:610-623.
2016
-
Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS‐CAN prospective study.
174:88-101.
2016
-
The genetic basis of asymptomatic codon 8 frame‐shift (HBB:c25_26delAA) β0‐thalassaemia homozygotes.
172:958-965.
2016
-
Laboratory measurement of the direct oral anticoagulants.
172:315-336.
2016
-
A phase‐II sequential case‐series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.
170:208-217.
2015
-
c.1058C>T variant in the SERPINC1 gene is pathogenic for antithrombin deficiency.
170:123-125.
2015
-
Thalidomide‐prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
168:511-517.
2015
-
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O6‐methylguanine DNA methyltransferase expression.
167:664-670.
2014
-
Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study.
166:130-139.
2014
-
A phase 2 study of HQK‐1001, an oral fetal haemoglobin inducer, in β‐thalassaemia intermedia.
164:456-458.
2014
-
Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab‐Indian haplotype is not benign.
164:597-604.
2014
-
Activated prothrombin complex concentrate for dabigatran‐associated bleeding.
164:308-310.
2014
-
How I manage heavy menstrual bleeding.
162:721-729.
2013
-
Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta‐analysis.
161:192-203.
2013
-
Cytoadherence in paediatric malaria:ABOblood group,CD36, andICAM1 expression and severePlasmodium falciparuminfection.
159:223-236.
2012
-
Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin.
156:259-264.
2012
-
Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism.
155:511-513.
2011
-
Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements.
154:704-714.
2011
-
Palliative care: what approaches are suitable in developing countries?.
154:728-735.
2011
-
Prospective multicentre cohort study of heparin‐induced thrombocytopenia in acute ischaemic stroke patients.
154:378-386.
2011
-
Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.
153:612-622.
2011
-
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial.
152:771-776.
2011
-
Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.
152:52-60.
2011
-
The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.
149:3-13.
2010
-
Characterisation of the British α0‐thalassaemia deletion: evidence of a founder effect in Newfoundland, Canada.
147:150-152.
2009
-
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?.
146:142-149.
2009
-
Bone marrow cells from patients with Shwachman‐Diamond syndrome abnormally express genes involved in ribosome biogenesis and RNA processing.
145:806-815.
2009
-
Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma.
143:355-360.
2008
-
A multicentre randomised clinical endpoint study of parma 5 computer‐assisted oral anticoagulant dosage.
143:274-283.
2008
-
Clinical features and outcome of pulmonary embolism in children.
142:808-818.
2008
-
Studies in haemoglobin E beta‐thalassaemia.
141:388-397.
2008
-
Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate.
140:589-592.
2008
-
Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation.
140:214-217.
2008
-
Characterisation of a novel 49·3 kb Gγ(Aγδβ)0‐thalassaemia deletion in seven families of Asian descent.
138:125-126.
2007
-
Leukaemia‐related gene expression in bone marrow cells from patients with the preleukaemic disorder Shwachman–Diamond syndrome.
137:537-544.
2007
-
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.
136:203-211.
2007
-
The status of new anticoagulants.
134:3-19.
2006
-
Shwachman–Diamond syndrome: an inherited model of aplastic anaemia with accelerated angiogenesis.
133:558-561.
2006
-
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism.
133:68-77.
2006
-
Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange.
132:204-209.
2006
-
Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute protocols: effect of age and risk stratification of disease.
129:803-810.
2005
-
Bone marrow biopsy in thrombocytopenic or anticoagulated patients.
129:562-563.
2005
-
Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.
125:613-620.
2004
-
Intravenous (IV) anti‐D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti‐D by FcγRIIa and FcγRIIIa polymorphisms.
124:511-518.
2004
-
Heparin‐induced thrombocytopenia: pathogenesis and management.
123:373-374.
2003
-
Heparin‐induced thrombocytopenia: pathogenesis and management – Response to Rasheed Saad.
123:374-375.
2003
-
The IgG subclasses of platelet‐associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura.
122:818-824.
2003
-
Heparin‐induced thrombocytopenia: pathogenesis and management.
121:535-555.
2003
-
Clinical manifestations associated with the aberrant expression of the soluble granulocyte–macrophage colony‐stimulating factor receptor in patients presenting with haematological malignancies.
121:86-93.
2003
-
The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces.
120:315-324.
2003
-
Prolonged complete remission in two cases of acute promyelocytic leukaemia treated with atra alone.
117:768-768.
2002
-
Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen‐induced platelet aggregation by nitroprusside*.
117:664-675.
2002
-
Regulation of plasminogen activator inhibitor‐1 secretion by urokinase and tissue plasminogen activator in rat epithelioid‐type smooth muscle cells.
117:151-158.
2002
-
Mechanisms responsible for the failure of protamine
to inactivate low‐molecular‐weight heparin.
116:178-186.
2002
-
Hb H hydrops foetalis syndrome: a case report and review of literature.
115:72-78.
2001
-
The storage defects in grey platelet syndrome and αδ‐storage pool deficiency affect α‐granule factor V and multimerin storage without altering their proteolytic processing.
113:871-877.
2001
-
Compound Heterozygosity For Triplicated α‐Globin Gene and (– –SEA) α‐Globin Gene Deletion: Implication For Thalassaemia Screening.
110:493-499.
2000
-
Measurement of endogenous and exogenous alpha‐granular platelet proteins in patients with immune and nonimmune thrombocytopenia.
106:762-770.
1999
-
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.
105:1109-1113.
1999
-
A prospective study of protein‐specific assays used to investigate idiopathic thrombocytopenic purpura.
104:442-447.
1999
-
Expression of p210 and p190 BCR‐ABL due to alternative splicing in chronic myelogenous leukaemia.
103:711-715.
1998
-
Laboratory abnormalities in thrombotic thrombocytopenic purpura.
103:1031-1036.
1998
-
Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group..
103:1031-1036.
1998
-
Major surgery seems not to influence HIV disease progression in haemophilia patients.
103:10-14.
1998
-
Studies of multimerin in patients with von Willebrand disease and platelet von Willebrand factor deficiency.
103:20-28.
1998
-
PRE‐OPERATIVE FACTOR Xa–TFPI AND POST‐OPERATIVE VENOUS THROMBOSIS.
101:793-792.
1998
-
PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA.
97:762-767.
1997
-
Correspondence.
97:504-510.
1997
-
Fibrinogen degradation products in patients with the Quebec platelet disorder.
97:497-503.
1997
-
A diagnostic test for heparin‐induced thrombocytopenia: detection of platelet microparticles using flow cytometry.
95:724-731.
1996
-
Post-transfusion alloimmunization..
95:573-574.
1996
-
Probable regulation of factor VIIa–tissue factor and prothrombinase by factor Xa–TFPI and TFPI in vivo.
95:738-746.
1996
-
The epitope specificity of heparin‐induced thrombocytopenia.
95:161-167.
1996
-
Age‐related changes in factor VII proteolysis in vivo.
94:407-412.
1996
-
Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura.
93:421-426.
1996
-
Heparin‐induced skin lesions.
92:494-497.
1996
-
Plasmin accelerates platelet‐dependent prothrombinase formation without activating the platelets.
92:458-465.
1996
-
Time for a new acute myeloid leukaemia classification?.
92:247-248.
1996
-
A prospective study to determine the frequency and clinical significance of alloimmunization post‐transfusion.
91:1000-1005.
1995
-
2 ‐Chloro‐deoxyadenosine therapy for giant lymph node hyperplasia.
91:668-670.
1995
-
The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis.
91:742-746.
1995
-
Measurement of factor Xa‐antithrombin III in plasma: relationship to prothrombin activation in vivo.
90:669-680.
1995
-
Bacterial infection‐associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies.
90:332-335.
1995
-
The use of anti‐D to improve post‐transfusion platelet response: a randomized trial.
89:163-168.
1995
-
Thrombin binding to platelets and their activation in plasma.
88:592-600.
1994
-
The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals.
86:347-350.
1994
-
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery.
85:745-750.
1993
-
B‐cell lymphoma of recipient origin 9 years after allogeneic bone marrow transplantation for T‐cell acute lymphoblastic leukaemia.
85:99-102.
1993
-
Heparin‐induced thrombocytopenia and thrombosis: clinical and laboratory studies.
84:322-328.
1993
-
OMITTING THE ANTIGLOBULIN CROSS-MATCH.
83:522-523.
1993
-
OMITTING THE ANTIGLOBULIN CROSSMATCH.
83:521-523.
1993
-
Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.
82:729-734.
1992
-
PATHOPHYSIOLOGY OF HEPARIN‐INDUCED THROMBOCYTOPENIA.
82:778-779.
1992
-
Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent.
82:400-405.
1992
-
The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery.
82:391-399.
1992
-
The production of human monoclonal antiplatelet auto‐antibodies derived from human lymphocytes of normal origin: reactivity to DNA, anionic phospholipids and platelet proteins.
82:99-106.
1992
-
A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing.
81:579-584.
1992
-
HLA‐DR expression by platelets in acute idiopathic thrombocytopenic purpura.
81:552-557.
1992
-
Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patients.
81:539-544.
1992
-
Identification of an extensive ζ‐α globin gene deletion in a Chinese individual.
80:378-380.
1992
-
The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release.
79:296-301.
1991
-
Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation.
76:387-394.
1990
-
A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin–antithrombin complex, D‐dimer and fibrinogen/fibrin fragment E antigen.
74:471-479.
1990
-
Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura.
74:457-464.
1990
-
Platelet specific alloantigens on the platelet glycoprotein Ia/IIa complex.
72:534-538.
1989
-
Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study.
71:493-497.
1989
-
Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation.
71:265-269.
1989
-
A prospective comparison of four techniques for measuring platelet‐associated IgG.
71:97-105.
1989
-
Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families.
70:321-326.
1988
-
INDEPENDENT CLONAL ORIGIN OF COEXISTING CHRONIC LYMPHOCYTIC LEUKAEMIA AND MULTIPLE MYELOMA.
70:126-127.
1988
-
Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura.
66:509-513.
1987
-
Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides.
64:707-714.
1986
-
The haemorrhagic and antithrombotic effects of dermatan sulphate.
64:309-317.
1986
-
The haemorrhagic and antithrombotic effects of dermatan sulphate..
64:309-317.
1986
-
Platelet fragments do not contribute to elevated levels of platelet associated IgG.
61:707-715.
1985
-
PLATELET AUTOANTIBODIES IN SEPTICAEMIA.
61:589-591.
1985
-
The immunodepletion of factor VII from human plasma using a monoclonal antibody.
61:467-475.
1985
-
The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
60:695-704.
1985
-
Placental transport of low molecular weight heparin in the pregnant sheep.
59:103-108.
1985
-
The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
57:229-238.
1984
-
Quantitation of red cell membrane associated immunoglobulin in children with Plasmodium falciparum parasitaemia.
54:567-572.
1983
-
HAEMOPOIETIC ENGRAFTMENT WITH PERIPHERAL BLOOD CELLS IN THE TREATMENT OF MALIGNANT DISEASE.
51:181-187.
1982
-
Plasma betathromboglobulin and serum fragment E in acute partial stroke.
50:327-334.
1982
-
HEMATOPOIETIC ENGRAFTMENT WITH PERIPHERAL-BLOOD CELLS IN THE TREATMENT OF MALIGNANT DISEASE.
51:181-187.
1982
-
Transient Donath‐Landsteiner Haemolytic Anaemia.
48:425-434.
1981
-
Chronic Myeloid Leukaemia: Evidence for Basophil Differentiation and Histamine Synthesis from Cultured Peripheral Blood Cells.
45:13-21.
1980
-
Unequal α and β Globin mRNA in Reticulocytes of Normal and Mutant f/f Fetal Mice.
44:431-439.
1980
-
The Influence of Red Blood Cells on the Effects of Aspirin or Sulphinpyrazone on Platelet Adherence to Damaged Rabbit Aorta.
42:283-291.
1979
-
The Patterns of Fetal Haemoglobin Production in Leukaemia.
32:487-506.
1976
-
Foetal Erythropoiesis in Steel Mutant Mice.
29:553-565.
1975
-
Ethanol Inhibition of Haemoglobin Synthesis: In Vitro Evidence for a Haem Correctable Defect in Normal Subjects and in Alcoholics.
28:311-316.
1974
-
Investigation of the Mechanism of False Positive 125I‐Labelled Fibrinogen Scans.
26:469-473.
1974
-
Effect of Repeated Treatment of Rabbit Platelets with Low Concentrations of Thrombin on their Function, Metabolism and Survival.
25:675-689.
1973
-
Prolonged Prothrombin Time and Partial Thromboplastin Time in Disseminated Intravascular Coagulation not Due to Deficiency of Factors V and VIII.
24:725-734.
1973
-
Microangiopathic Haemolytic Anaemia (MHA).
23:45-52.
1972
-
Urokinase Therapy: Dosage Schedules and Coagulant Side Effects.
22:567-577.
1972
-
Globin Synthesis in Sideroblastic Anaemia I α AND β PEPTIDE CHAIN SYNTHESIS.
20:263-275.
1971
-
In‐Vitro Studies with Ancrod (‘Arvin’).
20:217-224.
1971
-
The effect of prostaglandin E1 on platelet function in vitro and in vivo.
19:559-571.
1970
-
Effects of Sulphydryl Inhibition on the Erythrocyte in Paroxysmal Nocturnal Haemoglobinuria.
18:269-278.
1970
-
Defective Synthesis of an Unstable Haemoglobin: Haemoglobin Koln (β98Val‐Met).
18:195-210.
1970
-
Microangiopathic Haemolytic Anaemia and Mucin‐forming Adenocarcinoma.
18:183-194.
1970
-
Alpha- and beta- peptide chain synthesis in sideroblastic anaemia..
17:607-608.
1969
-
‘Non‐Tropical Idiopathic Splenomegaly’ (‘Primary Hypersplenism’): A Review of Ten Cases and their Relationship to Malignant Lymphomas.
17:317-333.
1969
-
Organ Distribution of Fibrin in Disseminated Intravascular Coagulation.
17:73-81.
1969
-
Treatment of Patients with Microangiopathic Haemolytic Anaemia with Heparin.
15:603-622.
1968
-
Atypical congenital spherocytosis: evidence of abnormal permeability of K+..
15:323-324.
1968
-
Microangiopathic haemolytic anaemia: experimental production of fragmented erythrocytes in vitro..
15:322-323.
1968
-
Fibrinogen Catabolism in Microangiopathic Haemolytic Anaemia.
14:617-625.
1968
-
Microangiopathic Haemolytic Anaemia: Mechanisms of Red‐Cell Fragmentation: in Vitro Studies.
14:643-652.
1968
-
Microangiopathic Haemolytic Anaemia: the Experimental Production of Haemolysis and Red‐Cell Fragmentation by Defibrination in Vivo.
14:627-642.
1968
-
Intravascular Haemolysis with Experimentally Produced Vascular Thrombi.
13:868-891.
1967
-
Microangiopathic Haemolytic Anaemia: The Occurrence of Haemolysis in Experimentally Produced Vascular Disease.
13:135-142.
1967
-
Tissue Iron Stores in Sideroblastic Anaemia.
11:107-113.
1965
-
Microangiopathic Haemolytic Anaemia: The Possible Role of Vascular Lesions in Pathogenesis.
8:358-374.
1962
-
Incorporation of 32PO4 into phospholipids of blood platelets
1977
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)